Naucni Radovi

Efikasnije dejstvo kompletnog ekstrakta cvetova kanabisa u odnosu na izdvojen kanabidiol (CBD)

rundozuco

June 2, 2015

Autori – Ruth Gallily, Zhannah Yekhtin, Lumír Ondřej Hanuš
The Lautenberg Center for General and Tumor Immunology, The Hadassah Medical School, The Hebrew University of Jerusalem, Jerusalem, Israel; Department of Medicinal and Natural Products, Institute for Drug Research, The Hadassah Medical School, The Hebrew University of Jerusalem, Jerusalem, Israel
Email: ruthg@ekmd.huji.ac.il

Objavljeno: 10. 02. 2015.

Kanabidiol (CBD), jedan od glavnih sastojaka Kanabisa, pokazao se kao veoma snažan lek koji deluje protiv zapaljenja i anksioznosti bez psihotropskih efekata. Međutim, kada se daje intraperitonalno ili oralno, kao pročišćen proizvod, primećena je reakcija u obliku zvona koja ograničava njegovu kliničku upotrebu. U ovoj studiji, proučavali smo na miševima protivupalnih i antinosiseptivne aktivnosti (smanjenje osetljivosti na bolne stimuluse) standardizovanih biljnih ekstrakata izvedenih iz Cannabis sativa L, klona 202, koji je veoma bogat CBD-om i skoro da ne sadrži psihoaktivne sastojke. U potpunoj suprotnosti sa pročišćenim CBD-om, ekstrakt klona 202 kada se daje intraperitonalno ili oralno, obezbeđuje jasnu korelaciju između protivupalnih i antinosiseptivnih odgovora i doziranja, sa pojačanim odgovorom kod povećanja doza, što ovo biljno lečenje čini idealnom za kliničku upotrebu. Ekstrakt klona 202 je umanjio oticanje šapa kod miševa indukovano zimosanom, kao i bol, i sprečio proizvodnju TNFa (Tumor nekrozis faktora) in vivo. Vrlo je verovatno da se druge komponente iz ekstrakta udružuju sa CBD-om da bi se postiglo željeno anti-inflamatorno dejstvo koje može doprineti prevazilaženju reakcije u obliku zvona koji se javlja kod pročišćenog CBD-a. Iz tog razloga sugerišemo da je ekstrakt Kanabis klona 202 (Avidekel) superioran u odnosu na CBD za lečenje upalnih stanja.

Reference

[1]
Hazekamp, A., Ware, M.A., Muller-Vahl, K.R., Abrams, D. and Grotenhermen, F. (2013) The Medicinal Use of Cannabis and Cannabinoids—An International Cross-Sectional Survey on Administration Forms. Journal of Psychoactive Drugs, 45, 199-210.
http://dx.doi.org/10.1080/02791072.2013.805976

[2]
Mechoulam, R. (2012) Cannabis—A Valuable Drug That Deserves Better Treatment. Mayo Clinic Proceedings, 87, 107-109.
http://dx.doi.org/10.1016/j.mayocp.2011.12.002

[3]
Greydanus, D.E., Hawver, E.K., Greydanus, M.M. and Merrick, J. (2013) Marijuana: Current Concepts. Frontiers in Public Health, 1, 42.
http://dx.doi.org/10.3389/fpubh.2013.00042

[4]
Syed, Y.Y., McKeage, K. and Scott, L.J. (2014) Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis. Drugs, 74, 563-578.
http://dx.doi.org/10.1007/s40265-014-0197-5

[5]
Brenneisen, R. (2007) Chemistry and Analysis of Phytocannabinoids and Other Cannabis Constituents. Marijuana and the Cannabinoids, Chapter 2, 17-49.
http://dx.doi.org/10.1007/978-1-59259-947-9_2

[6]
Pertwee, R.G. (2008) The Diverse CB1 and CB2 Receptor Pharmacology of Three Plant Cannabinoids: Delta9-Tetrahydrocannabinol, Cannabidiol and Delta9-Tetrahydrocannabivarin. British Journal of Pharmacology, 153, 199-215.
http://dx.doi.org/10.1038/sj.bjp.0707442

[7]
Pacher, P. and Mechoulam, R. (2011) Is Lipid Signaling through Cannabinoid 2 Receptors Part of a Protective System? Progress in Lipid Research, 50, 193-211.
http://dx.doi.org/10.1016/j.plipres.2011.01.001

[8]
Malfait, A.M., Gallily, R., Sumariwalla, P.F., Malik, A.S., Andreakos, E., Mechoulam, R. and Feldmann, M. (2000) The Nonpsychoactive Cannabis Constituent Cannabidiol Is an Oral Anti-Arthritic Therapeutic in Murine Collagen-Induced Arthritis. Proceedings of the National Academy of Sciences USA, 97, 9561-9566.
http://dx.doi.org/10.1073/pnas.160105897

[9]
Mechoulam, R., Peters, M., Murillo-Rodriguez, E. and Hanus, L.O. (2007) Cannabidiol—Recent Advances. Chemistry & Biodiversity, 4, 1678-1692.
http://dx.doi.org/10.1002/cbdv.200790147

[10]
Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R. and Gallily, R. (2008) Cannabidiol Arrests Onset of Autoimmune Diabetes in NOD Mice. Neuropharmacology, 54, 244-249.
http://dx.doi.org/10.1016/j.neuropharm.2007.06.029

[11]
Kozela, E., Lev, N., Kaushansky, N., Eilam, R., Rimmerman, N., Levy, R., Ben-Nun, A., Juknat, A. and Vogel, Z. (2011) Cannabidiol Inhibits Pathogenic T Cells, Decreases Spinal Microglial Activation and Ameliorates Multiple Sclerosis-Like Disease in C57BL/6 Mice. British Journal of Pharmacology, 163, 1507-1519.
http://dx.doi.org/10.1111/j.1476-5381.2011.01379.x

[12]
Esposito, G., Filippis, D.D., Cirillo, C., Iuvone, T., Capoccia, E., Scuderi, C., Steardo, A., Cuomo, R. and Steardo, L. (2013) Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview. Phytotherapy Research, 27, 633-636.
http://dx.doi.org/10.1002/ptr.4781

[13]
Jamontt, J.M., Molleman, A., Pertwee, R.G. and Parsons, M.E. (2010) The Effects of Delta-Tetrahydrocannabinol and Cannabidiol Alone and in Combination on Damage, Inflammation and in Vitro Motility Disturbances in Rat Colitis. British Journal of Pharmacology, 160, 712-723.
http://dx.doi.org/10.1111/j.1476-5381.2010.00791.x

[14]
Gadó, K. and Gigler, G. (1991) Zymosan Inflammation: A New Method Suitable for Evaluating New Anti-Inflammatory Drugs. Agents and Actions, 32, 119-121.
http://dx.doi.org/10.1007/BF01983335

[15]
Grotenhermen, F. (2003) Pharmacokinetics and Pharmacodynamics of Cannabinoids. Clinical Pharmacokinetics, 42, 327-360.
http://dx.doi.org/10.2165/00003088-200342040-00003

[16]
Rocha, A.C., Fernandes, E.S., Quintao, N.L., Campos, M.M. and Calixto, J.B. (2006) Relevance of Tumour Necrosis Factor-Alpha for the Inflammatory and Nociceptive Responses Evoked by Carrageenan in the Mouse Paw. British Journal of Pharmacology, 148, 688-695.
http://dx.doi.org/10.1038/sj.bjp.0706775

[17]
Romano, B., Borrelli, F., Pagano, E., Cascio, M.G., Pertwee, R.G. and Izzo, A.A. (2014) Inhibition of Colon Carcinogenesis by a Standardized Cannabis Sativa Extract with High Content of Cannabidiol. Phytomedicine, 21, 631-639.
http://dx.doi.org/10.1016/j.phymed.2013.11.006

[18]
Capasso, R., Aviello, G., Borrelli, F., Romano, B., Ferro, M., Castaldo, L., Montanaro, V., Altieri, V. and Izzo, A.A. (2011) Inhibitory Effect of Standardized Cannabis Sativa Extract and Its Ingredient Cannabidiol on Rat and Human Bladder Contractility. Urology, 77, 1006.e9-1006e15.
http://dx.doi.org/10.1016/j.urology.2010.12.006

[19]
De Petrocellis, L., Ligresti, A., Schiano Moriello, A., Iappelli, M., Verde, R., Stott, C.G., Cristino, L., Orlando, P. and Di Marzo, V. (2013) Non-THC Cannabinoids Inhibit Prostate Carcinoma Growth in Vitro and in Vivo: Pro-Apoptotic Effects and Underlying Mechanisms. British Journal of Pharmacology, 168, 79-102.
http://dx.doi.org/10.1111/j.1476-5381.2012.02027.x

[20]
Russo, E.B. (2011) Taming THC: Potential Cannabis Synergy and Phytocannabinoid-Terpenoid Entourage Effects. British Journal of Pharmacology, 163, 1344-1364.
http://dx.doi.org/10.1111/j.1476-5381.2011.01238.x

[21]
Wagner, H. and Ulrich-Merzenich, G. (2009) Synergy Research: Approaching a New Generation of Phytopharmaceuticals. Phytomedicine, 16, 97-110.
http://dx.doi.org/10.1016/j.phymed.2008.12.018

Izvor: http://www.scirp.org/Journal/PaperInformation.aspx?PaperID=53912#.VW3OqVKHgvz